$RGC These positive data from the second efficacy trial bring us one step closer to improving the conditions and quality of life of patients and reducing the negative impact that ADHD and ASD have on patients and their families," said Yat-Gai Au, founder and CEO of Regencell. https://finance.yahoo.com/news/regencell-bios...00297.html